An update on dry eye disease molecular treatment: advances in drug pipelines

Bibliography

• Fauchais AL, Martel C, Vidal E. [Epidemiology and physiopathogy of Sjogren's syndrome]. Rev Prat 2012;622:218-20
   Google Scholar
• The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:93-107
   Google Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:75-92
   Google Scholar
• Linsen C, Missotten L. Physiology of the lacrimal system. Bull Soc Belge Ophtalmol 1990;238:35-44
   PubMedGoogle Scholar
• Dilly PN. Structure and function of the tear film. Adv Exp Med Biol 1994;350:239-47
   PubMedGoogle Scholar
• Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;238:762-70
   Web of Science ®Google Scholar
• Kastelan S, Lukenda A, Salopek-Rabatic J, et al. Dry eye symptoms and signs in long-term contact lens wearers. Coll Antropol 2013;37(Suppl 1):199-203
   PubMedGoogle Scholar
• Lemp MA. Epidemiology and classification of dry eye. Adv Exp Med Biol 1998;438:791-803
   PubMed Web of Science ®Google Scholar
• Bron AJ. Diagnosis of dry eye. Surv Ophthalmol 2001;45(Suppl 2):S221-6
   PubMed Web of Science ®Google Scholar
• Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 2012;315:472-8
   Web of Science ®Google Scholar
• Viso E, Rodriguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci 2012;536:2601-6
   Web of Science ®Google Scholar
• Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:108-52
   Google Scholar
• Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004;233:272-85
   Web of Science ®Google Scholar
• Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf 2009;7:199-211
   PubMed Web of Science ®Google Scholar
• Pult H, Purslow C, Murphy PJ. The relationship between clinical signs and dry eye symptoms. Eye (Lond) 2011;254:502-10
   Web of Science ®Google Scholar
• Narayanan S, Miller WL, Prager TC, et al. The diagnosis and characteristics of moderate dry eye in non-contact lens wearers. Eye Contact Lens 2005;313:96-104
   Google Scholar
• Turner AW, Layton CJ, Bron AJ. Survey of eye practitioners' attitudes towards diagnostic tests and therapies for dry eye disease. Clin Experiment Ophthalmol 2005;334:351-5
   Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;194:477-82
   Web of Science ®Google Scholar
• Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 2012;313:271-85
   Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013;321:19-41
   Web of Science ®Google Scholar
• Pult H, Purslow C, Berry M, et al. Clinical tests for successful contact lens wear: relationship and predictive potential. Optom Vis Sci 2008;8510:E924-9
   Google Scholar
• Sambursky R, Davitt WF III, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013;1311:24-8
   Google Scholar
• Blackie CA, Solomon JD, Scaffidi RC, et al. The relationship between dry eye symptoms and lipid layer thickness. Cornea 2009;287:789-94
   Google Scholar
• Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011;1515:792-8; e1
   Web of Science ®Google Scholar
• McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol 2012;574:293-316
   Web of Science ®Google Scholar
• Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010;5112:6125-30
   Web of Science ®Google Scholar
• Sacks LV, Shamsuddin HH, Yasinskaya YI, et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000 – 2012. JAMA 2014;3114:378-84
   Web of Science ®Google Scholar
• Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res 2001;221:8-18
   Web of Science ®Google Scholar
• The Gallup Organization I. The 2008 gallup study of dry eye sufferers. Multi-Sponsor Surveys, Inc, Princeton, NJ; 2008
   Google Scholar
• Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;52:163-78
   Google Scholar
• Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;315:186-93
   Google Scholar
• Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;4512:4293-301
   Web of Science ®Google Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B 2006;78:675-8
   Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;1074:631-9
   Web of Science ®Google Scholar
• Calias P, Cook C, Jaffe M, et al. Enhanced delivery of a therapeutic to ocular tissues through iontophoresis. WO2009108626; 2009
   Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol 2011;5:633-43
   PubMedGoogle Scholar
• Assil KK, Massry G, Lehmann R, et al. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg 1997;235:750-7
   Google Scholar
• Bron A, Denis P, Hoang-Xuan TC, et al. The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study. Eur J Ophthalmol 1998;81:16-21
   Google Scholar
• Kavuncu S, Horoz H, Ardagil A, et al. Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol 2008;284:281-5
   Google Scholar
• Vico-Ruiz E, Benitez-Del-Castillo-Sanchez JM, Cuina-Sardina R, et al. 0.1% dexamathasone and 1% rimexolone. A comparative study in the postoperative treatment after cataract extraction. Arch Soc Esp Oftalmol 2009;846:299-304
   Google Scholar
• Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol 2012;325:507-17
   Google Scholar
• McNamara T, Chandler SP, Kida T. Ophthalmic NSAIDS as adjuvants. US20110054031; 2011
   Google Scholar
• Walters TR, Goldberg DF, Peace JH, et al. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology 2014;1211:25-33
   Web of Science ®Google Scholar
• Wang QW, Yao K, Xu W, et al. Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of ocular inflammation and prevention of cystoid macular edema after phacoemulsification. Ophthalmologica 2013;2294:187-94
   Web of Science ®Google Scholar
• Prasher P. Acute corneal melt associated with topical bromfenac use. Eye Contact Lens 2012;384:260-2
   Web of Science ®Google Scholar
• Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci USA 2013;11010:3913-18
   Web of Science ®Google Scholar
• Barnes TM, Hou J, King BM. Chimeric IL-1 receptor type I agonists and antagonists. WO2012016203; 2012
   Google Scholar
• Furfine ES, Hou J, Collins K, et al. EBI-005: an Interleukin-1 receptor inhibitor designed for the treatment of dry eye syndrome. Association for research in vision and ophthalmology (ARVO) 2012; E-Abstract: 2340/A357
   Google Scholar
• Okanobo A, Chauhan SK, Dastjerdi MH, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012;1541:63-71
   Web of Science ®Google Scholar
• So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;92:R28
   Web of Science ®Google Scholar
• Venkiteshwaran A. Tocilizumab. MAbs 2009;15:432-8
   Google Scholar
• Sato T, Minakuchi S, Mochizuki M, et al. Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis. Clin Ophthalmol 2014;8:187-90
   PubMedGoogle Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011;195:382-3
   Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012;396:1294-5
   Web of Science ®Google Scholar
• Fishman P. Pharmaceutical composition comprising a3 adenosine receptor agonist (IB-MECA/CF-101) for treatment of psoriasis. WO2011027348; 2011
   Google Scholar
• Bar-Yehuda S, Luger D, Ochaion A, et al. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med 2011;285:727-31
   Google Scholar
• Ashar JN, Mathur A, Sangwan V. CF101 for dry eye. Ophthalmology 2011;1185:1011-12; author reply 2
   Google Scholar
• Bague S, Lambert G, Philips B, et al. Ophthalmic emulsions containing an immunosuppressive agent. US20128298569; 2012
   Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012;2012:604204
   PubMedGoogle Scholar
• Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea 2013;323:345-54
   Web of Science ®Google Scholar
• Lemp AM, Baudouin C, Amrane M, et al. Poor correlation between dry eye disease (DED) signs and symptoms in a Phase III randomized clinical trial. Association for research in vision and ophthalmology (ARVO) 2011; E-Abstract: 3821/D954
   Google Scholar
• Yavuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cyclosporin a delivery. ScientificWorldJournal 2012;2012:194848
   PubMed Web of Science ®Google Scholar
• Burnier J, Gadek T, Naud F. Crystalline pharmaceutical and methods of preparation and use thereof. US20118080562; 2011
   Google Scholar
• Sun Y, Zhang R, Gadek TR, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther 2013;29(4):395-402
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012;1536:1050-60; e1
   Web of Science ®Google Scholar
• Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther 2013;29(2):236-48
   PubMed Web of Science ®Google Scholar
• Brazzell RK, Haque RM, Brubaker KE, et al. Method of treating dry eye disease with azithromycin. US20100190734; 2010
   Google Scholar
• Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;321:44-53
   Web of Science ®Google Scholar
• Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013;7:1797-803
   PubMedGoogle Scholar
• Utine CA. Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite) solution in the treatment of ocular infections. Clin Ophthalmol 2011;5:801-9
   PubMedGoogle Scholar
• Veldman P, Colby K. Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin 2011;514:43-52
   Google Scholar
• Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens 2012;382:73-9
   Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;171:1-14
   Google Scholar
• Rihl M, Ulbricht K, Schmidt RE, et al. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009;487:796-9
   Web of Science ®Google Scholar
• Yavuz S, Asfuroglu E, Bicakcigil M, et al. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int 2011;318:1045-9
   Web of Science ®Google Scholar
• Opremcak EM. Plaquenil toxicity. Insight 2013;383:15
   Google Scholar
• Vanderzee G, Tassi D. New trends in early diagnosis of hydroxychloroquine toxic retinopathy. Optometry 2012;835:200-7
   Google Scholar
• Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody. Semin Oncol 1999;265(Suppl 14):66-73
   Google Scholar
• Rogers JL, Serafin DS, Timoshchenko RG, et al. Cellular targeting in autoimmunity. Curr Allergy Asthma Rep 2012;126:495-510
   Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome. Ann Rheum Dis 2013;726:1026-31
   Web of Science ®Google Scholar
• Cumberlidge G, Lama T, Meerovitch K. Beta-turn peptidomimetic cyclic compounds for treating dry eye. US20128293713; 2012
   Google Scholar
• Wang ZX, Sun XG. The effect of nerve growth factor on proliferation and expression of mucin gene in human conjunctival goblet cells. Zhonghua Yan Ke Za Zhi 2007;4310:928-31
   Google Scholar
• Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res 2011;934:503-12
   Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol 2013;7:1275-85
   PubMedGoogle Scholar
• Tarnawski AS, Chai J, Pai R, et al. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 2004;492:202-9
   Web of Science ®Google Scholar
• Iijima K, Ichikawa T, Okada S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009;547:1500-7
   Web of Science ®Google Scholar
• Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 2004;236:613-19
   Web of Science ®Google Scholar
• Sumida SI, Ishikawa S. A pharmaceutical composition comprising rebamipide. WO2009154304, US 20110124682; 2009
   Google Scholar
• Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;11912:2471-8
   Web of Science ®Google Scholar
• Ogawa T, Watanabe N, Okumura Y. Method for preventing or treating dry eye or disease caused therefrom. US19985830913; 1998
   Google Scholar
• Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence 2003;186:330-3
   Web of Science ®Google Scholar
• Shimoyama T, Fukuda Y, Fukuda S, et al. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol 1996;31(Suppl 9):59-62
   PubMedGoogle Scholar
• Jumblatt JE, Jumblatt MM. Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 1998;673:341-6
   Web of Science ®Google Scholar
• Murakami T, Fujihara T, Horibe Y, et al. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res 2004;362:89-93
   Web of Science ®Google Scholar
• Fujihara T, Murakami T, Nagano T, et al. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 2002;184:363-70
   Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 2012;9610:1310-15
   Web of Science ®Google Scholar
• Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond) 2012;2610:1363-8
   Web of Science ®Google Scholar
• Koh S, Ikeda C, Takai Y, et al. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol 2013;575:440-6
   Web of Science ®Google Scholar
• Business Wire. Santen and inspire announce approval of DIQUASTM for Dry Eye Treatment in Japan. Available from: http://www.businesswire.com/news/home/20100416005914/en/Santen-Inspire-Announce-Approval-DIQUASTM-Dry-Eye [Last accessed 3 January 2014]
   Google Scholar
• Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf 2013;114:246-58
   Google Scholar
• Simmons PA, Vehige J. Ophthalmic compositions useful for improving visual acuity. US20100184664; 2010
   Google Scholar
• Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2007;484:1559-67
   Web of Science ®Google Scholar
• Baudouin C, Cochener B, Pisella PJ, et al. Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol 2012;225:751-61
   Google Scholar
• McGinnigle S, Eperjesi F, Naroo SA. A preliminary investigation into the effects of ocular lubricants on higher order aberrations in normal and dry eye subjects. Cont Lens Anterior Eye 2014;37(2):106-10
   PubMed Web of Science ®Google Scholar
• McCann LC, Tomlinson A, Pearce EI, et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012;311:1-5
   Web of Science ®Google Scholar
• Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry 2011;821:38-43
   Web of Science ®Google Scholar
• Lee JH, Ahn HS, Kim EK, et al. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 2011;302:175-9
   Web of Science ®Google Scholar
• Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol 2010;1494:594-601
   Web of Science ®Google Scholar
• Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;862:181-4
   Web of Science ®Google Scholar
• Baeyens V, Bron A, Baudouin C. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Fr Ophtalmol 2012;356:412-19
   Web of Science ®Google Scholar
• Dumbleton K, Woods C, Fonn D. An investigation of the efficacy of a novel ocular lubricant. Eye Contact Lens 2009;353:149-55
   Web of Science ®Google Scholar
• Baeurle SA, Kiselev MG, Makarova ES, et al. Effect of the counterion behavior on the frictional–compressive properties of chondroitin sulfate solutions. Polymer (Guildf) 2009;507:1805-13
   Web of Science ®Google Scholar
• Konat Zorzi G, Contreras-Ruiz L, Parraga JE, et al. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol Pharm 2011;85:1783-8
   Web of Science ®Google Scholar
• Llamas-Moreno JF, Baiza-Duran LM, Saucedo-Rodriguez LR, et al. Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye. Clin Ophthalmol 2013;7:995-9
   PubMedGoogle Scholar
• Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome. Eur J Pharm Biopharm 1999;472:113-18
   Web of Science ®Google Scholar
• Villani E, Laganovska G, Viola F, et al. A multicenter, double-blind, parallel group, placebo-controlled clinical study to examine the safety and efficacy of T-Clair SPHP700-3 in the management of mild to moderate dry eye in adults. Cornea 2011;303:265-8
   Web of Science ®Google Scholar
• Fel A, Aslangul E, Le Jeunne C. Eye and corticosteroid's use. Presse Med 2012;414:414-21
   Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;1383:444-57
   Web of Science ®Google Scholar